Although VISTA-blocking antibodies are currently in Phase I clinical trials for solid tumor malignancies, this treatment remains untried in patients with brain tumors, and the effects of blocking VISTA in MB have not yet been explored. This evidence concerns the gene VSIR and brain neoplasm.